BioSpace News Archive

Coya Therapeutics, Inc., a clinical-stage biotechnology company developing biologics intended to enhance Treg function, released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman.

Castle Biosciences, Inc. announced new data demonstrating the ability of the DecisionDx®-SCC test to identify cutaneous squamous cell carcinoma tumors at a biologically high risk of metastasis in a subset of patients considered to be at a low risk of metastasis by traditional staging and Brigham and Women’s Hospital staging systems.

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the third quarter of fiscal 2023, which ended March 31, 2023.

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced the U.S. launch of PreserVision® AREDS 2 Formula soft gels plus coenzyme Q10.

AstraZeneca’s New Drug Application (NDA) for capivasertib in combination with FASLODEX® (fulvestrant) has been accepted and granted Priority Review in the US for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine-based regimen.

Anavex Life Sciences Corp. announced the publication of a relevant new peer-reviewed study in the American Journal on Intellectual and Developmental Disabilities, entitled ‘Rett Syndrome Behaviour Questionnaire in Children and Adults With Rett Syndrome: Psychometric Characterization and Revised Factor Structure’.

Crinetics Pharmaceuticals, Inc. announced that on June 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 331,800 shares of its common stock to 14 new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) will hold a video conference call on Tuesday, June 13, 2023, to update investors and analysts on the Phase 1 trial of its lead peptide-drug conjugate (PDC) candidate, sudocetaxel zendusortide (formerly TH1902), for the treatment of solid tumors.

CalciMedica Inc. announced that The Nasdaq Stock Market LLC has approved CalciMedica’s application for the relisting of the Company’s common stock on the Nasdaq Capital Market.

Vaccitech plc (NASDAQ: VACC) (the Company, we or us) today announced the dosing of the first patient in the PCA001 clinical trial (NCT05617040).